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ABSTRACT 
The influenza virus infects millions of individuals each year. "Between one 
percent and twenty-six percent of persons aged 18 to 64 years may be infected 
with influenza annually and the associated work absenteeism can result in 
substantial societal costs" (Bridges, et. al., 2000, page 1655). No one is immune 
from the virus and variations in the strains from year to year result in annual 
outbreaks or epidemics. 
For the working population, the risk of complications from the flu is much 
lower than in the high-risk groups. However, lost workdays, decreased 
productivity, and the spread of the infection to co-workers, cost businesses 
millions of dollars each year. The focus of this paper is to look at the role of the 
Occupational Health Nurse (OHN) in developing and implementing an influenza 
immunization program at the work site. 
Controversy exists regarding the cost benefit of such a program and 
confounding factors, such as a shortage of the vaccine and a dramatic increase in 
price have occurred since the most recent cost benefit studies have been 
published. However, the efficacy of the influenza vaccine and the lack of 
significant adverse reactions have been well documented. 
A well planned, efficiently implemented, and extensively evaluated onsite 
influenza immunization program will be efficacious in reducing absenteeism and 
lost productivity. 
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CHAPTER I 
Introduction 
The influenza virus infects millions of individuals each year. "Between one 
i 
f--
percent and twenty-six percent of persons aged 18 to 64 years may be infected 
with influenza annually and the associated work absenteeism can result in 
substantial societal costs" (Bridges, et. a!., 2000, page 1655). Influenza can be a 
serious medical problem for which only limited treatment is available. There are 
a vast number of over-the-counter medications for treatment of the symptoms, but 
very few antiviral drugs are available. The antiviral meclications include f 
Amantadine, Rimantacline, Zanamivir, and Oseltamivir, with specific mechanisms 
for treating influenza A but have no effect on influenza B (GlaxoSmithKline, 
2002; Burton, 2000). These antiviral medications only shorten the course of 
illness by one to two days, but are much more effective in decreasing the number 
and severity of complications (Burton, 2000). Although young healthy adults do 
not suffer the higher rates of mortality associated with influenza that are seen 
among individuals over 65 or those who have chronic cliseases, they do 
experience increased morbidity, lost workdays, and lost productivity due to 
influenza infection. 
Several agencies including the Centers for Disease Control and Prevention 
(CDC) recommend the influenza vaccine be given annually to certain individuals 
in what are considered high-risk groups. Although adults younger than the age of 
50 years are not considered to be at high risk for serious complications from the 
flu, they still suffer from the consequences of lost work time. It has been 
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documented that worksite influenza immunization programs produce significant 
health and economic benefits for both the employee and their employers (Dille, 
1999). Nichol documented that the cost from absenteeism was significantly 
reduced for workers in all age groups who received the influenza vaccine (Nichol, 
et. a!., 1996). One study has shown the cost benefit of providing workplace 
vaccination programs to healthy working adults had a mean savings of $13.66 per 
person (Nichol, 2001). 
Over the years the recommendations regarding who should be vaccinated have 
greatly expanded. The most recent information from the U.S. Public Health 
Service's Advisory Committee on Immunization Practices (ACIP) recommends 
that physicians administer the influenza vaccine to any person who wishes to 
reduce the likelihood of becoming infected with the flu (MMWR, April 2002). 
The Occupational Health Nurse (OHN) must consider several factors when 
making the decision to offer a workplace immunization program. What are the 
benefits to the company, the employee, the employee's family and the community 
as a whole? Is the program going to be cost-effective? Are there liabilities that 
the company may incur? Are there other less costly strategies for preventing the 
spread of influenza among healthy adult workers? Will the employees be 
receptive of the program? 
In 1996, the National Institute for Occupational Safety and Health (NIOSH) 
published the National Occupational Research Agenda (NORA). "This agenda 
which identified 21 research priorities, was designed to and continues to provide a 
framework to guide occupational safety and health research in the next decade for 
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the entire occupational safety and health community" (Rogers, 2002, page 301). 
The purpose of NORA is to focus research in the areas with the highest likelihood 
of reducing workplace injury and illness. It is important to note that infectious 
diseases are an integral part of the NORA research priorities (Rogers, 2002). As 
stated by Dr. Bonnie Rogers in her book, Occupational Health Nursing Concepts 
and Practice (page 36), " ... prevention marks the cornerstone for occupational 
health nursing practice." The occupational health nurse's role is to improve, 
protect, maintain, and restore the health of the worker (Rogers, 1994). This paper 
will describe the strategies the OHN must use in developing and implementing an 
influenza immunization program to prevent the spread of the high! y contagious 
influenza viruses that occur annually throughout the world. 
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CHAPTER2 
Literature Review 
Why would an organization want to develop and implement an influenza 
immunization program within the workplace rather than in the community since 
i-
the "flu" is not considered a work-related illness? While it is true that the actual 
disease process is not an outcome associated with or arising out of the 
performance of one's job duties, the illness does impact lost work days and 
productivity. Although the elderly and those individuals with chronic diseases are 
more vulnerable to the complications of the flu, anyone can get the flu. 
According to the CDC, "most people who get the flu will recover in one to two L 
I weeks, but some will go on to develop life-threatening complications" (CDC, 2002). In addition, the CDC states that about 10% to 20% of the U.S. population 
(millions of people) will get the flu each year. 
Influenza Virus 
Definition 
Influenza, commonly called the "flu", is a highly contagious viral infection of 
the nose, throat and lungs that is one of the most severe illnesses of the winter 
season. Symptoms of the disease include sudden onset of fever, myalgia, sore 
throat, nonproductive cough, headache, muscle aches, weakness, and extreme ~-
fatigue. Influenza is easily transmitted from person to person by inhaling droplets 
containing viral particles that are suspended in the air from the cough or sneeze of 
an infected individual, or from direct contact (CDC, 2002). Influenza virus may 
survive for up to 48 hours on nonporous surfaces such as doorknobs, telephone 
receivers, computer keyboards, etc. (Homeland Health Specialists, 2002). The 
4 
virus enters the body through the mucous membranes of tbe eyes, nose, or mouth 
and then reproduces rapidly in the host. 
The very young, the elderly, and those with chronic diseases are at greater risk 
for increased morbidity and mortality due to complications from influenza L 
infections. Complications may include sinusitis, bronchitis, otitis media, 
pneumonia, and death (World Health Organization, 1999). Influenza is a 
seasonal disease that can undergo minor genetic changes or mutations from 
season to season, leading to the development of new strains (A ventis Pastuer, 
1998). 
Although millions of individuals are infected with influenza each year, some 
I flu seasons are classified as epidemics or pandemics. An epidemic occurs when an infectious disease is present in several geographic regions, among many people 
at the same time. A pandemic occurs when the epidemic reaches worldwide r 
' 
proportions (American Museum of National History, 1999). The influenza virus. 
has caused many epidemics throughout history and has also been responsible for 
three pandemics in the last century (CDC, 2002). 
Types 
There are three types of influenza viruses: influenza A, B, and C. Influenza A 
can infect both humans and animals and causes pandemics, epidemics, and 
seasonal outbreaks. Influenza Band Conly infect humans. Outbreaks of 
Influenza B have led to epidemics (National Foundation of Infectious Diseases, 
October 2000). Influenza C produces only mild illness, similar to the common 
cold, and has not been responsible for epidemics or pandemics (NFID, 2000) (see 
Table 2.1). 
5 
Table 2.1 
CHARACTERISTICS OF THE DIFFERENT TYPES OF INFLUENZA 
CHARACTERISTICS 
Produces infection in humans 
Produces infection in 
animals/birds 
Causes epidemics 
Causes pandemics 
Mild illness only 
INFLUENZA A 
YES 
YES 
YES 
YES 
NO 
INFLUENZAB INFLUENZAC 
YES YES 
NO NO 
YES NO 
NO NO 
NO YES 
6 
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The disease is characterized as an acute respiratory illness that is not clinically 
differentiated from other acute respiratory illnesses but must be confirmed by 
laboratory tests such as serum antibody tests, virus cultures, or rapid diagnostic 
tests such as Directigen Flu A, Flu OIA, Quick Vue or ZstatF!u (GiaxoSmithK!ine, 
2002). 
Influenza A viruses are divided into subtypes based upon proteins on the 
surface of the virus. These proteins are called hemagglutinin (H) and 
neuraminidase (N). Each strain of influenza virus is labeled according to the type 
of protein. For example, the strains of influenza A present at this time in the 
Northern Hemisphere, are A(HlNl) and A(H3N2) (CDC, 2002). Variations in 
membrane proteins hemagglutinin and neuraminidase allow the viruses to escape 
immunity to previous strains (Earn, et. a!., 2002). Influenza B is not divided by 
subtypes and is identified only as influenza B. 
Changes in Influenza A are brought about by antigenic "shifts or drifts." A 
shift in the virus means that the strain has an abrupt major change that results in a 
new hemagglutinin or neuramindase (CDC, 2002). Shifts only occur occasionally 
and most people have little or no immunity to the new strains. Such a shift can 
lead to a pandemic. Drifts, however, are the gradual accumulation of mutations in 
the hemagglutinin or neuramindase. This occurs annually and is the trigger for 
epidemics (Schneider, 2000). 
Both subtypes of influenza A and the strain of influenza B are included in the 
production of the annual influenza vaccine. Because the development of the 
vaccine takes months to complete, the actual composition of the vaccine is based 
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upon predictions of which strains will be circulating for a given year. The 
efficacy of the influenza vaccine is dependent upon how well the strains used to 
manufacture the vaccine "match" the strains causing the illness (NFID, 2000). 
Obviously, when the vaccine closely matches the circulating strains of the virus 
which are present in the community the efficacy of the vaccine increases. j_ 
Historical Perspective 
The flu is one of the oldest and most common diseases known to man. 
Influenza was first described by Hippocrates in 412 BC and the first well-
described pandemic of an influenza-like disease occurred in 1580 (World Health 
Organization, February 1999). Three pandemics due to influenza A have 
The largest number of deaths due to influenza occurred between 1918 and 
I occurred in the past century (Earn, et. al., 2002). 
1919 during what has been named the Spanish flu pandemic. After World War I, 
this virulent strain of influenza reached every part of the world within one year 
(Zackowitz, 2002). In the United States during the Spanish flu pandemic, 50,000 
people died and as many as 20 to 50 million people may have died worldwide. 
The Spanish flu was unique because almost half of the deaths were among young, 
healthy adults (CDC, 2002). 
Two other pandemics, one in 1957, "Asian flu," and one in 1968, "Hong Kong 
flu," caused wide spread morbidity but had much lower mortality rates (Subbarao, 
2001, p. 9). The Asian flu contributed to about 70,000 deaths in the U.S. It was 
first identified in China in February 1957 and spread to the U.S. by June 1957. 
The Hong Kong flu was first identified in Hong Kong in early 1968 and spread to 
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the U.S. later that year. The Hong Kong flu caused an estimated 34,000 deaths in 
the United States (CDC, 2002). However, the cumulative mortality and morbidity 
rates for influenza are largely due to seasonal epidemics (Earn, et. a!., 2002). 
Epidemics, or outbreaks, are confined to a limited region and occur virtual! y 
every year, but vary in intensity. An outbreak commonly lasts about five to six 
weeks with no more cases reported for another year. A typical epidemic follows a 
characteristic pattern (see Figure 2.1). 
In closed communities such as nursing homes, an influenza epidemic may 
infect up to 60% of the residents. Epidemics of the flu generally occur in the 
Northern Hemisphere between December and April and between May and 
September in the Southern Hemisphere. In the tropical regions, outbreaks most 
often develop during the rainy season (GlaxoSmithKline, 2002). 
Morbidity/Mortality 
In an average year, more than 20,000 deaths and 200,000 hospitalizations 
occur in the U.S. due to influenza (NFID, 2000). Influenza is not a recordable 
disease; however, it is estimated that 10% to 20% of the population is infected 
with influenza each season (CDC, 2002). Of those who are infected, one percent 
will require hospitalization and among that group as much as eight percent will 
die. These figures are for the general population and include all age ranges, high 
and low risk individuals, and healthy adult workers (CDC, 2002). Influenza and 
influenza-related complications rank as the sixth leading cause of death in the 
United States (Immunization Practices Advisory Committee, 1992). 
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Figure 2.1 
CHARACTERISTICS OF A TYPICAL EPIDEMIC 
+ In the beginning there is an increase in the number of children developing 
fever. 
+ Cases reach a peak in 2 - 3 weeks. 
+ An increasing number of adults report influenza-like symptoms. 
+ Absenteeism from work and school peaks. 
+ Increased hospital admissions for patients with pneumonia, heart problems, 
and exacerbations of chronic respiratory diseases. 
+ There is a subsequent corresponding rise in deaths from these conditions. 
Source: Worldwide Vaccines- GlaxoSmithK!ine (2002) 
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The attack rate for healthy adults ranges from 5% to 15%, with about 45% of 
these cases requiring medical attention (Nichol, 2001). Although there are 
associated lost workdays with the illness, working adults tend to continue to work 
while ill, or return to work before they are fully recovered, thus exposing their 
coworkers to the disease. Because of these differences, when the OHN is 
developing the recommendations for a worksite immunization program, 
information regarding the impact of influenza upon healthy working adults must 
be separated from the health effects upon the general population. 
Recommendations 
Centers for Disease Control and Prevention (CDC) 
The Advisory Committee on Immunization Practices (ACIP) is an arm of the I ,.. 
l 
CDC, which publishes annually the current recommendations for the distribution 
and administration of the influenza vaccine (see Figure 2.2). 
While the CDC is considered to be the world authority on infectious diseases 
and its recommendations are the basis for standards of practice, it does not have 
regulatory authority. This is important to remember in light of the past two years' 
shortage of vaccine. Although the CDC clear! y outlined who should receive the 
vaccine, because of the shortage and the purchasing powers of large corporations, 
many of the individuals defined as high risk were not necessarily the first ones to 
be vaccinated when the vaccine became available. The 2002 CDC/ACIP 
recommendations addressed this problem. 
II 
Figure2.2 
RECOMMENDATIONS FOR ANNUAL INFLUENZA IMMUNIZATIONS 
• persons aged~ 50 years;* 
• residents of nursing homes and other long-term care facilities that house 
persons of any age who have long-term illnesses; 
• adults and children ~ 6 months of age who have chronic heart or lung 
conditions, including asthma; 
• adults and children ~ 6 months of age who need regular medical care or 
had to be in a hospital because of metabolic diseases (like diabetes), 
chronic kidney disease, or weakened immune system (including immune I system problems caused by medicine or by infection with human 
immunodeficiency virus [HIV/AIDS]); 
• children and teenagers (aged 6 months to 18 years) who are on long-term 
aspirin therapy and therefore could develop Reyes Syndrome after the flu; 
and 
• women who will be more than 3 months pregnant during the flu season. 
*People 50-64 years of age who do not have chronic (long-term) medical 
conditions might not be at high risk for serious complications from the flu. 
However, about 26% of people aged 50-64 years have high-risk conditions and 
are at increased risk for flu-related complications. Beginning in 2000, flu 
immunization was recommended annual! y for all people 50-64 years of age to 
increase the number of high-risk 50-64 year olds who received a flu shot. 
Source: Centers for Disease Control and Prevention (July 9, 2002) 
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In addition to the recommendations in Figure 2.2, ACIP added five principal 
changes or updates as follows: 
1. The optimal time to receive influenza vaccine is during the months of October 
and November. However, because of vaccine distribution delays during the 
past two years, ACIP recommends that vaccination efforts in October focus on 
persons at greatest risk for influenza-related complications and health-care 
workers and that vaccination of other groups begin in November. 
l 
2. Vaccination efforts for all groups should continue into December and later, for L 
as long as vaccine is available. 
3. Because young, otherwise healthy children are at increased risk for influenza-
I related hospitalization, influenza vaccination of healthy children aged 6- 23 
months is encouraged when feasible. Vaccination of children aged;::: 6 r 
months who have certain medical conditions continues to be strongly 
recommended. 
4. The 2002-2003 trivalent vaccine virus strains are A/Moscow/10/99 (H3N2)-
like, A/New Caledonia/20/99 (H1N1)-like, and B/Hong Kong/330/2001-like 
strains. 
5. A limited amount of influenza vaccine with reduced thimerosal content will 
be available for the 2002-2003 influenza season (MMWR, 2002). 
Recommendations by Other Health Care Entities 
A ventis Pastuer, a prominent vaccine producer, clearly defined high-risk 
groups as individuals over the age of 65 years. However, the company did not 
address the new recommendations concerning people older than 50 years, 
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children ages~ 6 months to 23 months, nor did they delineate the immunization 
schedule (Aventis Pasteur, 1998). Aventis Pasteur's recommendations were 
published on their website in 1998 and had not been updated in the past four 
years. 
Homeland Health Specialists, Inc., promoted influenza vaccinations on their 
website. The first two pages are devoted to documenting the seriousness of the 
illness and the fact that anyone over nine years of age may receive the vaccine 
from them. Corporations are encouraged to schedule a flu shot clinic and to 
"hurry" because Homeland Health Specialists' calendar was filling fast for the 
2002 flu season. It wasn't until the fifth page that recommendations were given 
for older adults and high-risk individuals. As with Aventis Pasteur, the newest 
CDC/ ACIP recommendations were not incorporated into the information. 
However, Homeland Health Specialists, Inc., updated their website in 2002 
(Homeland Health Specialists, Inc., 2002). 
While multiple sources may provide valuable information, the most recent and 
accurate recommendations for annual influenza immunizations are still provided 
by the Centers for Disease Control and Prevention. Of the other sources of 
recommendations reviewed, including Aventis Pastuer, Homeland Health 
Specialists, Inc, and GlaxoSmithKiine, almost every one cited the CDC/ ACIP 
recommendations but they were not necessarily the most recent recommendations. 
Cost to Society 
Each year over 110 million workdays are lost because of infection with 
influenza with associated costs to U.S. businesses of more than $7 billion in sick 
pay and lost productivity (Noonan, 2000). According to Wayne N. Burton, J\tlD, 
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Senior Vice-President and Corporate Medical Director for Bank One, the costs 
are somewhat less with 15 to 80 billion work days lost in the U.S. annually and a 
cost of $3 billion to U.S. businesses (Burton, 2000). In data compiled by Kristin 
L 
Nichol, M.D., in 1995, annual cases of influenza resulted in 200 million days of 
restricted activity, 100 million days of bed disability, 75 million days of 
absenteeism from work, and 22 million visits to a health care provider. 
Influenza affects up to 25% of the population each year. Less than 25% of 
' 
the population aged 18 to 64 received the flu immunization in 1997, yet the L 
effect upon this age group is substantial. The average case of influenza usually 
lasts five to six days, with a large number of episodes resulting in three to four 
days of bedrest and an additional three days of work absenteeism (Nichol, 
2001). 
Current Gaps in the Literature 
The findings concerning the efficacy of the influenza vaccine for young, 
healthy, adults have been inconsistent (Grotto, et. al., 1998). Cost benefit 
analysis studies were completed prior to the shortage of the vaccine and the 
associated increase in costs for the vaccine (Nichol, 2001; Dille, 1999; Fitzner, et 
al, 2000). Data showing positive cost benefits for immunizing individuals who do 
not fall into a high-risk category are no longer valid because the cost of the 
vaccine is based upon the pre-shortage price. In 1998 the cost of the influenza 
vaccine for a multi-dose vial of ten doses from the medical supply company 
QuickAid, was $21.50. Today, that same vial even at a discount rate is $132.00 
(see Table 2.2). 
15 
$150.00 
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Table 2.2 
COST OF INFLUENZA VACCINE PER YEAR 
Vaccine Costs 
• Unit Dose 
• Multi-dose \Aal 
(10 doses/\Aal) 
Source: QuickAid Medical and Edwards Medical Supply 
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Live, attenuated intranasal influenza virus vaccines, are being introduced and 
may have a higher protection rate, but also have higher costs per person. One 
study conducted by Nichol, et.al., (1999) concluded that the intra-nasal vaccine 
was effective in healthy working adults. However, the study focused on reduction 
in lost workdays, but did not include a cost benefit analysis. 
Studies to assess the effects of vaccine supply delays upon those in the high 
risk groups as well as healthy adults between the ages of 18 years and 64 years are 
important, particularly if the delay in inoculating healthy adults will lead to 
increased cases of influenza among this population. This is critical in light of the 
new recommendation that individuals in the high risk groups be inoculated in 
October and healthy adults in November (MMWR, 2002). 
While reduction in the number of cases of influenza has remained unchanged, 
the cost of the vaccine has soared. In 2000, one of the largest manufacturer's of 
the influenza vaccine was forced to stop the production of the vaccine due to non-
compliance with FDA regulations for the manufacture of vaccines (Edwards, 
2000). Other companies were not prepared to fill the orders that had been 
submitted to this company, resulting in a significant delay in the manufacture and 
delivery of the vaccine to clinics. Businesses that had ordered the vaccine in 
March were the first to receive the vaccine, rather than health care clinics. This 
meant that many individuals with chronic illnesses, those over the age of 64, 
and/or those who were immunocompromised did not receive the vaccine before 
healthy adult workers. Again in 2001 there was a shortage and a slight delay in 
the delivery of the vaccine. 
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The events of 2000 and 2001 led to a dramatic increase in the cost of the 
vaccine. The OHN must make the necessary cost adjustments when utilizing 
previous studies for documenting the cost benefits of the proposed influenza 
vaccine campaign. Studies conducted prior to 2001 were conducted when the 
cost of the vaccine was as low as $2.00 per injection. In 2002 the cost of a single 
injection ranged from $6.00 to $10.00 per injection, thus cost benefits may not be 
as substantial as reported in the earlier studies. 
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CHAPTER3 
INFLUENZA IMMUNIZATION IN THE WORKPLACE 
Business Concerns 
Absenteeism, Replacement and Overtime Costs 
The majority of workers in America are 18 to 64 years of age. The influenza 
vaccine is only recommended for a small portion of these employees, yet each 
year millions of Americans "come down with the flu." Traditionally, healthy 
working adults have not been included in campaigns targeting individuals who 
should receive the influenza vaccine. Each year between 5% and 15% of these 
individuals lose work time due to acute infection, yet many 18- 64 year olds also 
come to work ill (Nichol, 2001). 
When employees are out of work for three or four days, it is usually not 
feasible to bring in temporary help, yet the work must be completed. To fill in the 
gap, co-workers often have to work overtime to meet production quotas and 
deadlines. A 2000 Canadian study examined the costs of employee absenteeism 
and found that direct and indirect costs combined in lost production accounted for 
17% of payroll in 1997 (Watson Wyatt Worldwide, 2000). 
Absenteeism in administrative and executive personnel results in additional 
costs as work may be postponed. Meetings may be cancelled or rescheduled, 
travel plans rearranged, etc., all of which result in indirect costs associated with 
the absenteeism. 
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Interruption of Service and/or Product Delivery 
One facet of customer service that has been widely promoted in the past ten 
years is the production concept of "Just in Time" Inventory Systems. The "Just 
in Time"' concept schedules materials to arrive exactly when they are needed in 
the production process (MarketVolume, 2002). The system has allowed 
American companies to cut down the amount of inventory kept in their 
warehouses. This manufacturing technique works well when there is a stable 
source of supply. However, when supply is disrupted due to a shortage in 
manpower, the lack of inventory often results in plant shutdowns (Schuster, 
2001). 
If a company repeatedly fails to meet the customer's deadlines for delivery of 
raw or intermediate materials, that customer will ultimately take his business 
elsewhere. Even though the severity of the illness among healthy adults may only 
result in three to five days away from work, during an epidemic as much as 50% 
of a department may be out at one time (Nichol, 2001). Using an average income 
of $15.00 per hour, direct costs associated with absenteeism ranged from $360.00 
to $600.00 per employee. If ten employees were out of work for three days due to 
influenza, the direct cost of the absenteeism would be $3,600.00. This does not 
include indirect costs such as overtime, temporary staffing, or lost production. As 
the epidemic spreads throughout a company, more interruptions in production and 
delivery will occur. 
Lost or Reduced Sales and Productivity 
Healthy adults infected with influenza not only lose time from work, but when 
acutely ill, they lose some ability to perform reaction time tasks similar to that 
seen with alcohol consumption (Nichol, 2001). Working while acutely ill results 
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in significant reduction in productivity. This increases the chance of spreading or 
extending the epidemic because individuals are typically infectious from tbe day 
before symptoms begin until approximately five days after the onset of illness 
(MMWR, 2002). 
Health Benefit Cost 
The cost benefits of the inactivated influenza vaccine in reducing influenza 
illness and its complications for persons aged 65 and older are well-documented 
(Aventis Pastuer, 1998; MMWR, 2002; WHO, 1999). However, the benefits of 
an annual influenza vaccination campaign for healthy adults younger than 65 
years of age are less clear (Bridges, et. a!., 2000). When documenting the health 
benefit costs for a specific illness or prevention of that illness, it is necessary to 
examine the real-time costs that are charged back to the business as well as the 
indirect costs associated with lost work days (Nichol, et. al.,l995). 
In developing the cost-effectiveness report for a specific company, the OHN 
must determine what benefits are already provided by tbe company's health 
insurance plans, associated costs for both the employee and the company, and to 
what extent the benefits are utilized. However, the majority of companies rarely 
do this. While larger companies may have this capability, small companies 
seldom do it unless they have support from their third party administrators in 
providing disease/illness specific costs per illness/employee. Visits to the 
physician's office or admission to the hospital are coded according to the 
complications that brought the individual to seek medical care, such as pneumonia 
or sinusitis. Influenza may be a secondary diagnosis but is not always listed 
because laboratory confirmation is not routinely done. 
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As documented by Sessa, et. al, (2001), yearly influenza epidemics are not 
only associated with substantial loss of productivity, but there is also an increased 
pharmaceutical expenditure related to the excess prescription of antibiotics to treat 
the related bacterial complications. 
Therefore, when completing the cost benefit analysis, estimates may need to be 
made based upon the data available for the region. For instance, Nichol, (2001), 
utilized the American Medial Association's Socioeconomic Monitoring System 
Core Survey for physician's fees, lists of diagnostic tests, and medications 
associated with visits to the physician for evaluation and treatment of upper 
respiratory tract infections. 
Implied Employee Benefits 
No one is immune from the influenza virus. Therefore, it is suggested that any 
measures used to reduce the risk of infection are beneficial to the general 
population as well as those individuals in the high-risk groups. In theory, if 
healthy adults are given the influenza vaccine, they will either be prevented from 
developing the illness or face only very mild symptoms due to the illness. 
Vaccination will also reduce transmission from person to person because healthy 
adults, as well as individuals with chronic diseases, will have developed 
antibodies to the current strain of influenza (CDC, 2002). 
In addition to the reduction in lost workdays, the vaccinated worker will not 
need to seek medical care for treatment of the illness or its complications. 
Prevention of Illness 
The influenza vaccine efficacy rate, as documented by a randomized trial 
among health care professionals at John Hopkins University Hospital and School 
of Medicine, was 88% for Influenza A and 89% Influenza B. This resulted in 9.9 
days of absence per 100 subjects that received the vaccine versus 21.1 days of 
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absence per 100 subjects for individuals that did not receive the vaccine (Nichol, 
et. al., 1999). 
The efficacy of the vaccine in reducing laboratory-confirmed illness is in the 
range of 70% to 90%, when there is a good match between the circulating viruses 
and the corresponding vaccine strains (Nichol, 2001). 
Decreased Severity of Illness 
The consequences of the introduction of a new variation of influenza A into 
the general population can be dramatic and may lead to a pandemic (Subbarao, 
2001). Two hundred World Health Organization laboratories in 79 countries 
maintain global surveillance of the influenza virus. Through this collaborative 
effort, the virus is isolated worldwide throughout the year. From this surveillance 
data predictions are made concerning which strains of influenza will be 
circulating in the coming year (NFID, 2000). As stated earlier, when the vaccine 
closely matches the circulating strains, the vaccine is much more effective 
(Nichol, et. a!., 1995). 
Reduction in Complications 
Rapid changes in the circulating types of influenza virus make it necessary to 
reformulate the composition of the vaccine each year. "Prevention and control 
are thus the only realistic means of dealing with influenza" (WHO, 1999, page 1). 
Even if the vaccine cannot protect the person from the flu, it may protect them 
from severe complications or even death (NFID, 2000). In addition, the CDC 
stated in April 2002 that although antiviral medications are now available, these 
medications are not a substitute for vaccination. New intranasal vaccines are still 
being evaluated and may provide even greater protection (Nichol, et., a!., 1999). 
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Effects on Family 
More studies need to be instituted to evaluate the effects of the adult worker 
influenza immunization program upon the family unit. The studies by Nichol 
(2001), Dille (1999), and Fizner, et. a!., (2000) reviewed the indirect costs and 
savings to the business or the employee, but did not address the benefit or lack of 
benefit of the immunization program on the family. ACIP does recommend the 
vaccination for individuals who are a "household member" in close contact with 
persons at high risk (MMWR, 2002). 
When workers are immunized the family benefits from the decrease in 
exposure to infected individuals. Influenza is more easily spread among 
individuals that live together, Immunization of the healthy adult workers in the 
family decreases the risk that these individuals will carry the virus home to other 
family members. This is especially critical when there are family members with 
chronic illnesses, that are immunocompromised, or under the age of six months 
(CDC, 2002). 
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CHAPTER4 
PROGRAM PLANNING/IMPLEMENTATION 
A useful model to guide program planning and implementation is the health 
promotion model developed by Rogers (1994 ). This model incorporates the key 
components of program assessment, program planning, program implementation, 
and program evaluation, which are integral to a successful program. It is easily 
applied to an influenza immunization program at the workplace. Each of the steps 
will be discussed in detail (see Figure 4.1). 
Program Assessment 
The first step in planning any type of program for the work site is the 
assessment of the worker population. The OHN must understand the 
demographic characteristics of the population such as number of employees, age 
range, male/female ratio, level of education and language composition (Travers, 
1994). The initial review of demographics should include the above 
characteristics and highlight those employees who fall within any of the high-risk 
groups targeted by the CDC and ACIP as the recommendations were recently 
changed to include immunizing people aged 50 years and older. The OHN should 
also have a firm grasp on which employees have chronic illnesses, as well as 
employees who live with individuals in the high-risk groups. If available, this 
information should be gathered during the assessment phase and would be a 
crucial component in promoting the immunization program. 
With respiratory illnesses more prevalent during the fall and winter in the 
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Figure 4.1 
SYSTEMATIC APPROACH TO DEVELOPING 
A WORKPLACE 
INFLUENZA IMMUNIZATION PROGRAM 
Influenza Immunization Program Assessment 
Employee Demographics Work Environment Corporate Structnre 
Age, Race, Gender, Sex, Tools to Gather Corporate Philosophy 
Socioeconomic Status Data 
Employee Perception of 
Susceptibility 
Program Planning 
I I 
Goals & Advisory Marketing Resources 
Obiectives Committee Strate!!ies 
\ I 
Program Implementation 
I I 
l Budget Education and l Schedule Clinics 
~ Marketing / I 
Program Evaluation 
I Targets Met I 
I Cost Effectiveness Reduction in 
Absenteeism 
Source: Occupational Health Nursing Concepts and Practice, Rogers (1994) 
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Northern Hemisphere, the OHN must assess the work environment during these 
seasons. Do workers come in closer contact during these months? Are doors 
kept closed, is humidity up or down, are employees encouraged to come to work 
even if ill, and is there sufficient housekeeping to destroy viral particles left on 
desks, doorknobs, and telephones? 
The OHN must also understand the corporate philosophy and structure. If the 
philosophy of the company does not encompass employee health and wellness, 
the OHN may find it necessary to persuade management about the benefits of 
such programs. "Fostering a supportive environment or changing an environment 
to encourage a concept of health will go a long way in improving ultimate health 
behavior and outcomes" (Rogers, 1994, p. 298). 
The program needs the support of both the workers and management to be 
successful. Buy-in from management and the employees assures a more 
successful campaign. The structure of the corporation must be such that the 
employees are encouraged and allowed to participate in the programs that are 
offered. If the company operates 24 hours a day, seven days a week, management 
must be willing to alter the work processes so that employees are allowed time to 
participate in the immunization program. 
Utilization of the Health Belief Model, developed by Hochbaum, Kegeles, and 
Rosenstock will aid the OHN in identifying the workers' perceived susceptibility, 
perceived seriousness, and perceived threat of developing influenza (Rogers, 
1994). The Health Belief Model (HBM) is based upon the premise that an 
individual will participate in a health behavior to prevent disease based upon four 
basic parameters. 
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When applying the HBM to an influenza immunization program, the OHN is 
assessing the employees': 
+ Perception of their susceptibility to the flu, 
+ The seriousness of the disease or its complications if they should 
contract the flu, 
+ The person's understanding of the potential benefit of the flu vaccine, 
and 
+ The person's perception of barriers to taking the vaccine (see Table 
4.1). 
It has been documented that workers who had higher scores for susceptibility, 
seriousness, benefits, cues to action, knowledge, and health motivation with lower 
scores for barriers, were more likely to accept the immunization (Blue, 2002). 
One method of collecting data about the worker is an employee survey. By 
administering a health survey, the OHN is fostering employee ownership of the 
program. Analyzing absentee records, employee health encounter logs, and 
insurance data for the past flu season, gives the OHN a better understanding of the 
impact the flu season had upon the worker population. 
The administration and evaluation of an employee questionnaire/survey must 
be completed early in the year in order for the OHN to establish the amount of 
vaccine to be ordered. Also, by administering the questionnaire in January or 
February, while respiratory illnesses are still prevalent, the employees should 
have better recall of past infections. Once spring and summer arrive, it is difficult 
to remember the severity of last winter's illness (see Figure 4.2). 
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Table 4.1 
HEALTH BELIEF PARAMETERS 
APPLIED TO AN INFLUENZA IMMUNIZATION PROGRAM 
Parameter Low High 
Understanding/Perception Understanding/Perception 
Perception of Susceptibility I am too young to get the Anyone may contract the 
flu. flu. 
Perception of Seriousness The flu is just a bad cold. The flu may have serious 
complications. 
Understanding of the lllness The flu shot will give me The flu shot has a high 
the flu. likelihood of preventing the 
flu. 
Barriers to Taking the My insurance doesn't cover My company provides the 
Vaccine the flu shot. flu vaccine free of charge at 
work. 
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Another source of information is the company health history questionnaire. If 
the questionnaire is administered to employees on a periodic basis, then this 
information may be recovered from the individual medical records. More general 
information may be obtained from the review of insurance claims, but in light of 
the newly enacted regulations of the Health Insurance Portability and 
Accountability Act of 1996, these records may not be as readily accessible. 
I 
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Figure 4.2 
INFLUENZA SURVEY 
In preparation for this year's flu season, we must order our vaccine by the 
end of April. Please complete the following questionnaire and return to 
Medical Services by March 15. 
Please circle yes or no 
1. I am 50 years old or older. 
2. I have a chronic illness such as diabetes or heart disease. 
3. In the past I have taken the flu shot. 
4. I live with a family member who has a chronic illness 
such as diabetes or heart disease. 
5. I am imrnunocompromised. 
6. I live with a family member who is imrnunocompromised. 
7. I have children who will be at least 6 months of age by 
November ofthis year. 
8. I receive the flu shot from my physician. 
9. If the flu shot were offered at work, for a nominal fee 
I would take it. 
10. If the flu shot were offered free of charge at work, I 
would take it. 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
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Program Planning 
The second step in the process for developing a successful influenza 
immunization program is the planning phase. This includes forming an advisory 
committee. setting goals and measurable objectives, determining additional 
program implementation resources, identifying marketing strategies and 
programmatic strategies/activities, and setting a timeline for completion of 
activities (Rogers, 1994). 
The advisory committee should be composed of a representative from top 
management, the benefits coordinator, employee representatives, the occupational 
health nurse, and departmental managers (Rogers, 1994). The committee would 
assist by recommending dates, times, and places for the immunizations to be 
given as well as aid in promoting the program. The committee would also 
provide input on the goals and objectives to be met by the influenza immunization 
program. Such goals might include a target reduction of 10% in absenteeism or a 
goal that 70% of the employees will receive the vaccine. Although the committee 
may not have responsibility for the actual implementation of the program, they 
can be instrumental in getting other employees to participate in the program. 
It is imperative that program goals and health objectives are identified to 
guide the program and provide a means for evaluating its success. Goals need to 
be measurable and provide the documentation of the success or failure of the 
program. For example, one goal of the immunization program might be a 65% 
return rate for the influenza survey by the deadline. The goal is measurable and 
will provide key data when documenting the rationale for the program. 
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When the program is to be provided directly by the OHN, an assessment of 
resources is needed (Dille, 1999). Critical resources that are needed include the 
following: 
• Demographic data regarding the worksite population, production area in 
relation to the OH clinic, and the identification of employees in the 
CDC/ACIP defined high-risk groups. 
• Space needs relative to the flow of the employees into and out of the 
immunization area, a waiting area, access to running water, and emergency 
supplies/equipment. 
• Medical supplies readily available and such items as needle containers need to 
be immediately accessible in the work area. 
• Vaccine information, consent forms, and administration records provided 
prior to the injection of the vaccine. 
• Health education materials developed and posted in the weeks prior to the 
start of the clinics. 
• OH clinic staffing adequate enough to prevent prolonged absence by the 
employees from their duties. 
• Data management maintained in the immunization area. 
• Use of computerized systems or laptops. 
Strategic to the program is the OHN' s ability to impart the need for and the 
benefits of the influenza vaccine, dispelling the myths about influenza and the 
vaccine, and reducing barriers for accessing the clinics (Blue & Valley, 2002) (see 
Table 4.2). 
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Table 4.2 
STRATEGIES FOR A SUCCESSFUL 
INFLUENZA IMMUNIZATION PROGRAM 
Strategies with Minimal Associated Costs 
Have a theme similar to the theme for children's immunization clinics-
"Be wise, immunize!" 
Take program to the departments 
Develop a group of recruiters 
Have "Bring a friend with you" campaign 
Send electronic reminders 
Advertise in company newsletter 
Strategies with Additional Costs 
Give each recipient a button or sticker, such as "Be kind to me, I've had my flu 
shot today." 
Offer incentives, prizes 
Foster competition between departments by offering a pizza party to the 
department with the highest percentage of participation 
Utilize colorful posters, brochures and other handouts to foster awareness of the 
program 
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During the planning phase, marketing strategies must also be identified and 
developed. Posters must be obtained, electronic messages written and distributed, 
and the survey must be developed, administered, and tabulated. Programmatic 
j 
strategies/activities should be built upon the results of the data gathering from the L 
survey, health history questionnaires, and the review of insurance claims. One 
example of a programmatic strategy would be to consider using a "flu-shot 
mobile." The OHN would take the supplies through the plant on a wheeled cart 
which makes giving the shots more convenient for the employees, decreases 
employee time away from the job posts, enhances the nurse's image, and 
increases employee participation (Blue & Valley, 2002). 
The OHN and the advisory committee need to establish a timeline that I 
F encompasses the assessment, planning, implementation, and evaluation of the 
program (see Table 4.3). Due to the shortage and delayed production of the 
vaccine in the past two years, it is critical that planning begin no later than 
February for an October program start date. The committee must be cognizant of 
the fact that corporations are encouraged to place their orders for the vaccine as 
early as March and no later than May (Edwards Medical Supply, 2002a). 
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Table 4.3 
TIMELINE FOR INFLUENZA IMMUNIZATION PROGRAM 
DATE ACTION 
Mid January Gather data on absenteeism for past year 
February/March Administer influenza survey to employees 
April Update procedures, consent form, and prescription order with 
Medical Director 
April/May Order vaccine 
June/Ju!y Develop and/or order educational and promotional materials 
August Contact supplier regarding the status of current year's vaccine 
supply 
September Monitor Centers for Disease Control and Prevention's 
recommendations for most efficacious date to begin 
vaccinations 
October Post dates, times, and places for immunization clinics 
November Initiate immunization program following CDC 
recommendations and Medical Director's written orders 
December Post reminders that the flu vaccine is still available 
January Evaluate success of program; begin gathering data from 
previous year 
February/March Solicit feedback from employees. Develop and present 
evaluation of program to management 
April Modify program as indicated by the evaluation 
May Order vaccine and continue the program cycle 
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Cost 
The Nichol study (2001) concluded that flu immunizations for healthy working 
adults resulted in an average of a net cost of $2.18 to a net savings of $32.97 per 
employee 95% of the time. It did not take into account the vaccine shortage or 
the substantial increase in the cost of the vaccine. 
However, the OHN must determine the direct and indirect costs associated 
with the seasonal spread of the influenza virus among the workforce before a 
monetary decision can be made regarding the program. Without comprehensive 
planning in the developmental stages, there is often little or insufficient data 
documenting the cost-effectiveness of the program (Dille, 1999). After an 
exhaustive review of the literature, it is still difficult to definitively establish the 
cost benefit of an influenza immunization program for healthy working adults. 
Business priorities will also drive the program. If a company's productivity is 
critical during the fall and winter months, then an influenza program would be 
more cost-effective than for a company whose busiest season is during the 
summer months. The total impact of an onsite immunization program cannot be 
measured until a comparison of pre-immunization years with the post-
immunization years is analyzed and considered with the efficacy of the vaccine 
against the circulating strains of influenza A and B. For example, it is not enough 
to compare the cost of administering the program versus the reduction in 
absenteeism from the previous year. The number of cases of influenza in the 
community (data that are available from the weekly MMWR) and its impact upon 
the workforce and their families must also be considered. 
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Ethical and Legal Considerations 
Ethical and legal ramifications of an onsite immunization program must be 
taken into account. The program must be administered under the direction of a 
physician. Standing orders for administering the vaccine and how to respond to 
adverse reactions must be written and signed by the physician who is supporting 
the program. For larger corporations the physician may be an employee. Other 
companies may contract with a private occupational health physician or with an 
occupational health clinic. The majority of vaccine suppliers will require a 
prescription authorization form that includes the physician's state license number, 
his/her Drug Enforcement Administration number, and the authorization form 
signed by a physician. This form also lists the individuals that the physician is 
authorizing to administer the immunizations. 
Consent forms must be developed and approved by legal counsel. The consent 
form may be incorporated with the immunization record. The Food and Drug 
Administration requires that the immunization record contain the name and 
address of the person administering the immunization, the date, dose, and route of 
administration of the vaccine, as well as the lot number, expiration date, and 
manufacturer. 
In the past some companies had been reluctant to offer onsite immunization 
programs in fear that any adverse reactions would result in an OSHA recordable 
incident, or workers' compensation claim. However, OSHA has made it clear 
that complications from onsite influenza immunization are not recordable (OSHA, 
2001). Nonetheless, the OHN must ensure that the physician's orders are 
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followed, good nursing practices are utilized, and that appropriate equipment and 
supplies are readily available. Failure to provide the appropriate standard of care 
could result in a malpractice suit against the nurse administering the vaccine and 
against the company, since workers' compensation would not be the exclusive 
remedy. 
Program Implementation 
The OHN must begin the implementation phase during the budgeting process 
for the year in which the program is to be administered. Money must be 
dedicated not only to the purchase of the vaccine but for the additional medical 
supplies such as needles/syringes, alcohol swabs, gloves, etc. Consideration 
needs to be given to the cost of educating the employees regarding influenza and I 
the influenza vaccine, as well as the cost of communicating the dates, times, and F 
locations of the "flu shot clinics." The nurse must also determine if money needs 
to be allocated for additional staffing or overtime during the immunization 
program. 
If the OHN is not going to administer the program, but rather consult with a 
vender to deliver the program, then the costs for such a program must be 
identified and budgeted. Medical supply venders cannot guarantee the cost of the 
vaccine until the beginning of the year in which it will be administered. 
Therefore, the OHN must rely on the costs generated during the current year. 
This only becomes a problem when a shortage of vaccine occurs as it did in 2000. 
The replacement vaccine more than doubled the price of the previous year and the 
costs went up again in 2001 and 2002 (Edwards Medical Supply, 2002b). 
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Not knowing how many people will actually take the vaccine leaves the OHN 
estimating how much vaccine to order. The order should be based on the goals 
developed during the planning phase. If the target goal is to vaccinate 35% of the 
employees, then enough vaccine should be ordered to accommodate this goal. It 
is important to remember that the vaccine does not expire until June of the next 
year. The vaccine can be given as late as February when community epidemics 
have been identified. 
A successful immunization program is one that is made available to all L 
employees at a time and place that is convenient for them (Homeland Health 
Specialists, 2002). The information should be widely communicated and 
exceptions made for individuals that could not get to one of the scheduled times. 
Dille (1999) stated that management support in the form of providing access to 
the influenza vaccine during work hours and supporting staffing and clinical 
space greatly impacted the acceptance of the program. 
With many businesses running 24 hours 7 days a week, it is vital that the OHN 
be familiar with the number of shifts, the days and times of shift changes, and the 
number of employees per shift. One company may have employees on eight, ten 
and twelve hour shifts, yet another may offer 36 hour shifts on the weekend with 
no work during the week. The immunization program must give each employee 
the opportunity to receive the vaccine at work. This means that the program 
should be offered over at least a four-week period, on varying days, and varying 
hours. The more accessible the program, the better the employee participation 
(Dille, 1999). 
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Once the employees are educated about the vaccine and are willing to 
participate in the program, it is essential that the clinic be set up and fully 
functional prior to the first employee corning in to the clinic. In addition to 
ordering supplies, procedures, standing orders, and protocols must be established. 
These must be developed in conjunction with the company's physician resources. 
The standing orders must include the vaccine, the dosage, route, and site of 
administration. Emergency procedures need to be clearly written and supplies 
readily available. The nurses and other occupational health staff must be trained 
in emergency response, including the administration of drugs such as epinephrine 
and cardiopulmonary resuscitation, in the event of an anaphylactic reaction to the 
Each employee must be given a copy of the CDC's Vaccine Information Sheet I ' vaccine. 
(VIS) for influenza to be read prior to receiving the vaccine (see Appendix). The 
CDC will provide a copy free of charge by calling the CDC in Atlanta, Georgia, 
or by downloading a copy from the website at www.cdc.gov. The employee must 
be given the opportunity to ask questions and receive answers before consenting 
to the immunization. Signed informed consent forms and the immunization 
administration record should be kept as part of the employee's non-occupational 
medical record. 
Program Evaluation 
Evaluation of the program begins during the planning phase. By stating 
specific measurable goals, the OHN will be able to document the effectiveness of 
the program. Goals should include a target number or percentage of employees 
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that are expected to receive the vaccine and what percentage reduction in 
absenteeism is expected due to the institution of the program. A critical 
component of the evaluation is the cost benefit analysis. As previously mentioned 
the formula must include the direct and indirect costs for the program. The costs 
expended must be deducted from the costs saved. Thus the cost of the program 
subtracted from the cost saved by the reduction in absenteeism will yield the cost 
benefit (or deficit) of the program (Dille, 1999) (see Table 4.4). 
Employee feedback is essential to the evaluation of the program. If the 
program is cost-effective, but the employees were not satisfied, future programs 
may not be well attended. When employee surveys are administered in January or 
February to begin collection of information for the next influenza immunization I program, the employees should be asked if they participated the past year and if 
they found the program beneficial. The information gathered from the 
questionnaire will assist in determining what changes, if any, need to be made to 
the program. 
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Table 4.4 
COST BENEFIT ANALYSIS FORMULA 
Direct costs: 
Cost of vaccine 
Cost of medical supplies 
Indirect costs: 
Cost of time away from job for employee 
Cost of medical services staff time 
Educational/communication costs 
Cost of incentives 
Direct costs + Indirect costs = Cost of Program 
Direct prevented costs: 
Cost of lost workdays 
Estimated cost of medical visits prevented 
Estimated cost of complications prevented 
Indirect prevented costs: 
Cost of reduced productivity 
Cost of reduction in benefits usage 
(Prevented direct and prevented indirect costs) - (Direct costs + indirect 
costs) = Cost benefit or deficit. 
I 
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ChapterS 
ROLE OF THE OCCUPATIONAL HEALTH NURSE 
Program Provided by OHN 
The OHN in collaboration with the company physician, company 
management, and employee input determines if a work site influenza 
immunization program would be accepted and beneficial to the health and well-
being of the employees. As researchers Nichol (2001), Dille (1999), and Bridges, 
et. al., (2000) have suggested, there are health and economic benefits resulting 
from healthy adult workers receiving an influenza vaccination. It is crucial that 
the OHN gather and analyze data from the worksite to ascertain if an influenza 
immunization program would be cost-effective and beneficial to the business. 
As the key driver of the program, the OHN must be committed to developing, 
implementing, and evaluating the program. The OHN does more than just order 
the influenza vaccine and post a notice of dates and hours when the vaccine will 
be offered. From inception to completion the OHN must be cognizant of the 
impact of the program upon the employees, management, and production. The 
program must be health-enhancing, worker-driven, and cost-effective (Rogers, 
1994). 
Immunizations Provided by Contract Service 
When it is not feasible for the OHN to directly provide the administration of an 
influenza immunization clinic, a contract service may be employed. However, 
contracting with an outside vendor does not relieve the OHN from the 
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responsibility for the planning, implementation, and evaluation of the program. 
The same steps must be followed with a few additions. 
First, the OHN must research the venders available in the community. If they 
f--
are willing to come on-site, will they be able to accommodate the shifts, days, 
and times that are most advantageous for the employees? Second, a contract 
must be written and reviewed by the company's legal counsel. Who is 
responsible for supplies, vaccine, emergency procedures, and disposal of 
medical wastes? Will the vender provide educational materials? Do they have 
protocols developed to be sure that state and federal regulations are being met 
vender carry adequate malpractice insurance? Third, will the program be cost- i concerning the administration of a prescription injectable medication? Does the 
F 
effective? Last, will the employees participate if the injections are not given 
directly by the OHN? 
All of these issues need to be addressed before signing on the "dotted line." 
No Immunizations Offered at the Worksite 
If the company decides not to offer the influenza immunization to the 
employees at the worksite, the OHN still needs to address the prevention and 
control of the spread of influenza among co-workers. Educational materials 
should be readily available and prominently displayed. Resources can be 
obtained free of charge from the Centers for Disease Control and Prevention, the 
World Health Organization, and influenza vaccine manufacturers. The 
information should dispel the myths regarding influenza and the vaccine, as well 
as contain measures for decreasing the spread of the virus. This should include 
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recommendations for hand washing, staying home when ill, and taking appropriate 
measures if an employee becomes ill while at work. 
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CHAPTER6 
DISCUSSION AND RECOMMENDATIONS 
Discussion 
According to Watson Wyatt Worldwide (2000), employee absenteeism is 
having a greater impact on the bottom line than ever before. Short -term absence 
costs, as a percentage of total payroll costs, have more than doubled from 2.0 
percent in 1997 to 4.2 percent in 1999. Each year over 100 million workdays are 
lost because of influenza and this costs American businesses more than $7 billion 
dollars a year in lost work days and lost productivity (Noonan, 2000). 
Unlike many viruses such as the common cold, infection with the influenza 
virus is preventable in 70% to 90% of the population with the use of influenza 
vaccines (Aventis Pastuer, 1998). The Advisory Committee for Immunization 
Practices now recommends the influenza vaccine for anyone over the age of 50 
(MMWR, 2002). 
i_ 
Multiple studies have been undertaken to evaluate the efficacy and cost f 
benefits of administering the influenza vaccine to healthy working adults, and 
providing that immunization at the worksite. The actual cost savings has varied 
with each study based upon the direct and indirect costs that were used in the cost 
benefit analysis. The efficacy of the vaccine was not disputed. Nichol, et. al. 
(1995), Bridges, et. al (2000), Grotto, et. al. (1998), and Lee, et. al. (2002), all 
demonstrated that the vaccine was effective in reducing the number of lost 
workdays, the amount of febrile illnesses, and a reduction in lost productivity. 
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Recommendations 
Based upon the literature review the efficacy of the influenza vaccine has been 
well-documented. In addition, the fact that the vaccine has few adverse effects 
makes it an ideal vaccine for general administration. 
Each OHN should determine if an on-site influenza program is feasible and 
advisable for his/her specific company (see Table 6.1.). First the OHN ought to 
examine previous absenteeism rates. This information will provide the starting 
point for determining the possible benefits of an on-site influenza immunization 
program. The OHN must assess the worker population for the number of 
employees or employees with family members that are in high-risk groups as 
identified by the CDC. The nurse is urged to establish management commitment i 
F and employee support for the program. 
The OHN will have to perform a cost benefit analysis to determine how the 
program will affect the bottom line. This should be done annually due to the fact 
that the virus may drift or shift, the changes in costs of the vaccine, and the 
number of employees who would be willing to participate in the program. 
The OHN must be aggressive in educating the employees by dispelling the 
myths regarding influenza and the vaccine. The benefits of receiving the vaccine 
must be presented to overcome the negative aspects such as the aversion to 
receiving an injection. The program must be convenient and timely for the 
employees. 
Finally, the OHN should provide a final evaluation of the program to 
management on an annual basis. This can be done in a report with individuals 
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Table 6.1 
IFLUENZA IMMUNIZATION PROGRAM 
On-site Versus Off-site Program 
On-site Clinic Off-site Clinic 
Pros Readily accessible to the employees Confidential L 
Less time away from work to obtain Other family members may be 
the vaccine immunized at the same time 
Minimal or no cost to employee Minimal or no cost to employee 
Group support from co-workers Less coercion from co-workers 
to participate in the program 
Management commitment Management commitment 
Cons Employees may feel pressured to Employees may not be allowed 
take the flu shot time off to go to the clinic I 
Other family members not able to Not as readily accessible 
participate in the program 
Direct and indirect costs may not Lack of familiarity with clinic 
allow the program to be cost staff may deter some workers 
beneficial 
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or percentage of employees vaccinated and the absentee rate for October through 
February compared to previous years. In addition to the statistical information, 
the report should provide information on what strategies worked, which didn't 
work, recommendations for the next year, and employee suggestions or ideas to 
enhance the program. Just as it is important to have management and employee 
input into the development of the program, it is essential to involve them in the 
evaluation of the program. 
Summary L 
Seasonal outbreaks, epidemics, and pandemics of influenza claim the lives of 
many individuals each year. The social and economic impact of influenza has 
been extensively documented from many countries, including the U.S., Canada, I Italy, and Finland. Annual influenza outbreaks are associated with increased 
morbidity and mortality among those individuals over the age of 65 years and 
among individuals with chronic illnesses (CDC, 2002). 
As documented by Bridges, et. al. (2000), Dille (1999), and Nichol (2001), 
influenza is a major cause of illness, a disruption to the daily lives, and a major 
cause of work absenteeism among healthy working adults. Healthy working 
adults between the ages of 18 years and 64 years have not been included among 
the priority groups targeted for receiving the influenza vaccine. 
A well-defined, well-planned, influenza immunization program provided by 
the occupational health clinic at the worksite for healthy adult workers has been 
efficacious in reducing absenteeism and lost productivity. However, it is not clear 
if such a program produces a cost benefit. During the 1998- 1999 flu season, a 
survey of 61 work-site clinics, community health departments, and other non-
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traditional sites such as drug stores and grocery stores showed an average charge 
for vaccination of $10.00 with a range of $5.00- $15.00 (Nichol, 2001) 
Nichol (2001) completed a study that concluded flu immunizations for healthy 
working adults resulted in an average net cost of $2.18 and a net savings of 
$32.97 per employee 95% of the time. She concluded that influenza vaccination 
of healthy working adults on average is a cost savings. 
However, these studies were conducted prior to the shortage of the vaccine in 
the year 2000. Following the shortage there was a tremendous increase in the 
costs of the vaccine. Additional studies will need to be completed to determine if 
on-site programs are truly cost-effective, but it is clear that the influenza vaccine 
is extremely effective in preventing illness and protecting the health of the 
worker. It is imperative that the OHN assess the worker population, the business 
conditions, and the predicted prevalence of influenza in the community when 
developing a campaign to provide influenza vaccination at the work site. 
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APPENDIX 
Influenza Vaccine What You Need to Know 
Vaccine Information Statement 
L 
Source: Centers for Disease Control and Prevention (2002) 
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INFLUENZA VACCINE 
(wHAT YO u N 
2002-2003 
( 1 I Why get vaccinated? ) 
Influenza ("flu") is a serious disease. 
It is caused by a virus that spreads from infected persons 
to the nose or throat of others. 
Influenza can cause: 
· fever · sore throat · chills 
· cough · headache · muscle aches 
Anyone can get influenza. Most people are ill with influ-
enza for only a few days, but some get much sicker and 
may need to be hospitalized. Influenza causes thousands 
of deaths each year, mostly among the elderly. 
Influenza vaccine can prevent influenza. 
( 2 I Influenza vaccine 
Influenza viruses change often. Therefore, influenza 
vaccine is updated each year. 
Protection develops about 2 weeks after getting the shot 
and may last up to a year. 
) 
Some people who get flu vaccine may still get flu, but they 
will usually get a milder case than those who did not get 
the shot. 
Flu vaccine may be given at the same time as other 
vaccines, including pneumococcal vaccine. 
Who should get influenza 
vaccine? 
People 6 months of age and older at risk for getting 
a serious case of influenza or influenza complications, 
and people in close contact with them (including all 
household members) should get the vaccine. 
E E D T 0 KN 0 w) 
An annual flu shot is recommended for: 
• Everyone 50 years of age or older. 
• Residents of long-term care facilities housing 
persons with chronic medical conditions. 
• Anyone who has a long-term health problem with: 
- heart disease - kidney disease 
- lung disease - metabolic disease, such as diabetes 
- asthma - anemia, and other blood disorders 
• Anyone with a weakened immune system due to: 
- HIV I AIDS or another disease that affects the 
immune system 
- long-term treatment with drugs such as steroids 
- cancer treatment with x-rays or drugs 
• Anyone 6 months to 18 years of age on long-term 
aspirin treatment (who could develop Reye 
Syndrome if they catch influenza). 
• Pregnant women who will be past the 3rd month of 
pregnancy during the flu season (usually November-
March, but past March in some years). 
• Physicians, nurses, family members, or anyone else 
coming in close contact with people at risk of 
serious influenza 
An annual flu shot is also encouraged for: 
• Healthy children 6-23 months of age, and their 
household contacts and out-of-home caretakers 
• Household contacts and out-of-home caretakers 
of infants less than 6 months of age 
• People who provide essential community services 
• People at high risk for flu complications who travel to 
the Southern hemisphere between April and Septem-
ber, or who travel to the tropics or in organized tourist 
groups at any time 
• People living in dormitories or under other crowded 
conditions, to prevent outbreaks 
• Anyone who wants to reduce their chance of 
catching influenza 
( ____ ln_fl_u_en_z_a _________ 6_1_2_6f_0_2 __ ~) 57 
I 
L 
! 
( 4 When should I get influenza vaccine? 
Most people need only one flu shot each year to prevent 
influenza. Children under 9 years old getting flu vaccine 
for the first time should get 2 shots, one month apart. 
The best time to get a flu shot is in October or November. 
But because the flu season typically peaks between 
January and March, vaccination in December, or even 
later can be beneficial in most years. 
Some people should be vaccinated beginning in September 
or October: people 65 years of age and older, people at 
high risk from flu and its complications, household 
contacts of these groups, health care workers, and 
children under 9 getting the flu shot for the first time. 
To make sure these people have access to available 
vaccine, others should wait until November. 
Some people should talk 
5 with a doctor before getting 
influenza vaccine. 
Talk with a doctor before getting a flu shot if you: 
I) ever had a serious allergic reaction to eggs or to a 
previous dose of influenza vaccine 
or 
2) have a history of Guillain-Barre Syndrome (GBS). 
If you have a fever or are severely ill at the time the shot 
is scheduled, you should probably wait until you recover 
before getting influenza vaccine. Talk to your doctor or 
nurse about whether to reschedule the vaccination. 
What are the risks from 
influenza vaccine? 
I 
A vaccine, like any medicine, is capable of causing serious 
problems, such as severe allergic reactions. The risk of a 
vaccine causing serious harm, or death, is extremely small. 
Serious problems from flu vaccine are very rare. The 
viruses in the vaccine have been killed, so you cannot 
get influenza from the vaccine. ---
Mild problems: 
•soreness, redness, or swelling where the shot was given 
•fever 
•aches 
Ifthese problems occur, they usually begin soon after the 
shot and last l-2 days. 
Influenza (6/26/02) Vaccine Information Statement 
Severe problems: 
• Life-threatening allergic reactions are very rare. If they 
do occur, it is within a few minutes to a few hours after 
the shot. 
• In I 976, swine flu vaccine was associated with a severe 
paralytic illness called Guillain-Barre Syndrome (GBS). 
Influenza vaccines since then have not been clearly 
linked to GBS. However, if there is a risk of GBS from 
current influenza vaccines, it is estimated at 1 or 2 cases 
per million persons vaccinated ... much less than the 
risk of severe influenza, which can be prevented by 
vaccination. 
7 
. 
What if there is a moderate 
or severe reaction? 
What should !look for? 
• Any unusual condition, such as a high fever or behavior 
changes. Signs of a serious allergic reaction can include 
difficulty breathing, hoarseness or wheezing, hives, 
paleness, weakness, a fast heart beat or dizziness. 
What should l do? 
• Call a doctor, or get the person to a doctor right away. 
• Tell your doctor what happened, the date and time it 
happened, and when the vaccination was given. 
• Ask your doctor, nurse, or health department to report 
the reaction by filing an Vaccine Adverse Event 
Reporting System (V AERS) form. Or call V AERS 
yourself at 1-800-822-7967, or visit their website at 
http://www .vaers.org. 
) 
(~B~~l_H_o_w __ c_a_n __ l_l_e_a_rn __ m __ o_re_?_. ______ ~) 
• Ask your doctor or nurse. They can give you the 
vaccine package insert or suggest other sources of 
information. 
• Call your local or state health department. 
• Contact the Centers for Disease Control and Prevention 
(CDC): 
-Calll-800-232-2522 (English) 
-Calll-800-232-0233 (Espaiiol) 
-Visit the National Immunization Program's 
website at http://www.cdc.gov/nip 
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES 
Centers for Disease Control and Prevention 
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